Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Rapid-Exchange Exit Contributes To 28% Decline In Vascular Sales

This article was originally published in The Gray Sheet

Executive Summary

A prolonged absence from the U.S. rapid-exchange delivery segment continues to encroach on Medtronic's once high-growth vascular intervention business unit
Advertisement

Related Content

Medtronic Drug-Eluting Stent Trial Aims For Equivalency, Approval In 2005
Medtronic Drug-Eluting Stent Trial Aims For Equivalency, Approval In 2005
Medtronic To Offer Vascular Access Closure System Under Scion Pact
Medtronic To Offer Vascular Access Closure System Under Scion Pact
Advertisement
UsernamePublicRestriction

Register

MT017062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel